Maggie L. Shaw

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.

A new study has investigated the influence of xanthine oxidase activity and mitochondrial DNA damage–associated molecular patterns on heart failure and cardiac remodeling among Black adults with resistant hypertension.

This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.

An abstract presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) bore out the results of an Italian investigation into a potential link between persons living with HIV (PLWH) taking newer antiretroviral therapies and neurocognitive disorder prevalence.

A new study from Japan has investigated possible associations between cognitive frailty and overall prognosis among elderly individuals who have heart failure.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).

This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.

This new study investigated the relationship between cardiac function and hemodynamics among individuals presenting with heart failure with preserved ejection fraction (HFpEF) and normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP).

This new subanalysis of data from the Rotterdam Study investigated life expectancy among women and men who live a healthy lifestyle and do or do not have heart failure.

A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.

This study investigated the relationships seen among premenopausal women with a family history of breast cancer and their breast tissue density as seen at their annual mammographic screening.

This new investigation, a subanalysis of participant data from the Atherosclerosis Risk in Communities study, examined race- and gender-based differences of heart failure (HF) risk at an older age.

This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.

A new study from North Carolina has investigated individuals’ experiences with and perspectives on their receipt of HIV-related care while incarcerated in 1 of 21 jails in the state.

This new study from investigators at University of Calgary investigated the potential of midwall striae fibrosis to predict hospital admission for heart failure.

This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.

This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.

A new report from the Republic of Korea compared outcomes among women following neoadjuvant chemotherapy and mastectomy who did or did not receive radiotherapy.

Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.

A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.

This study from Italy investigated potential associations between heart failure and comorbid cancer and whether the existence of heart failure predisposed individuals with both to a higher risk of death.

Despite being the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat, while new research shows treatment and diagnosis could benefit from minimally invasive liquid-based biopsy.

Although cardiovascular disease risk is well established in survivors of breast cancer, how cardiotoxicity from treatment influences development of cardiometabolic risk factors is not.

Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).

There is a persistent lack of effective treatments for heart failure with preserved ejection fraction (HFpEF), so in this study, investigators examined the impact of an atrial shunt among patients with this disease subtype.

As a social determinant of health, transportation barriers and their impact on health-related quality of life (HRQOL) were investigated among persons living with HIV in the Deep South.

In this new study from China, the link between left ventricular (LV) structural changes and mortality following coronary artery bypass grafting (CABG) was investigated among a patient cohort with heart failure with reduce ejection fraction.

This 9-month investigation looked into the potential for next-generation sequencing (NGS) at the point of care to increase turnaround time for biomarker testing results in advanced colorectal cancer (CRC).

This new analysis among patients with stage I to III breast cancer investigated outcomes in connection with 5 care delivery variables: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy initiation, and endocrine therapy continuation.